In the relentless pursuit of advancing diagnostics for Alzheimer’s disease (AD) and neurodegenerative disorders, a remarkable breakthrough has emerged from the laboratories of Tokyo, Japan. Researchers have successfully engineered the world’s first DNA aptamers that exhibit exceptional specificity and affinity for neurofilament light chain (NfL), a pivotal blood biomarker indicative of neurodegeneration. This innovation promises to revolutionize how clinicians detect and monitor the progression of AD, opening avenues for more accessible, affordable, and sensitive blood tests.
Alzheimer’s disease remains a paramount global health challenge, especially amidst an increasingly aging population. The disease insidiously erodes neurons long before clinical symptoms such as memory loss manifest. A critical hallmark of neurodegeneration is the damage and subsequent release of neuronal proteins like NfL into bodily fluids. NfL, a structural protein chiefly constituting axonal cytoskeletons, leaks into cerebrospinal fluid and bloodstream when neurons sustain injury. Detecting NfL levels in blood has thus been recognized as a window into ongoing neuronal degradation, making it a valuable biomarker for early diagnosis and disease monitoring.
Traditional assays for NfL quantification rely predominantly on antibody-based immunoassays, which although sensitive, are hampered by high production costs, batch variability, and modification inflexibility. Addressing these limitations, the Japanese research team generated short, synthetic single-stranded DNA molecules called aptamers. Aptamers function analogously to antibodies by binding target molecules with high precision; however, they are chemically synthesized, resulting in significant economic and technical advantages including batch-to-batch consistency and facile chemical modification.
The researchers employed a refined process known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to isolate aptamers with superior binding characteristics for NfL. SELEX iteratively screens massive libraries of random DNA sequences, enriching those with the highest affinity to the protein target while eliminating nonspecific binders. Following seven rigorous rounds of selection and negative filtering against unrelated tags, the team identified 86 candidate sequences, ultimately narrowing to 30 promising aptamers capable of recognizing the full-length human NfL protein.
Among these, two aptamers, designated MN711 and MN734, displayed remarkable binding affinities with dissociation constants of 11 nM and 8.1 nM respectively. These values underscore their binding strength on par with commercially available antibodies utilized in existing NfL assays. Crucially, these aptamers exhibited exceptional specificity, discriminating NfL from other Alzheimer’s-related proteins such as amyloid-beta and phosphorylated tau, thereby ensuring diagnostic precision.
Structural studies revealed that MN711 and MN734 recognize a defined region between amino acid residues 281 and 338 of the NfL protein. This segment corresponds to fragments observed in human plasma, reinforcing the physiological relevance of the aptamer-target interaction. Notably, the aptamers maintained their affinity and specificity in complex biological matrices, including human plasma, validating their potential for real-world diagnostic applications.
The translational significance of these aptamers is profound. Their small size and synthetic nature allow them to be chemically modified with functional moieties facilitating immobilization on sensor surfaces—metallic or carbon-based electrodes—integral to the development of compact electrochemical biosensors. This adaptability enables integration into point-of-care diagnostic platforms, potentially transforming neurodegenerative disease monitoring from specialized laboratories to accessible clinical settings or even home devices.
Associate Professor Kaori Tsukakoshi, leading this pioneering research, emphasizes that aptamers’ chemical versatility can dramatically streamline biosensor fabrication. Unlike antibodies, which are biological macromolecules with variable stability and laborious modification protocols, aptamers offer a modular, scalable approach to biosensor design. This advancement could lead to miniaturized, cost-effective devices capable of rapid, accurate NfL detection in blood, facilitating timely interventions and personalized patient care.
Beyond diagnostics, the implications extend into research on disease pathophysiology. By providing reliable tools to quantify NfL dynamics in patients, scientists can gain deeper insights into neural injury progression, therapeutic responses, and potentially discover new therapeutic targets. The aptamer platform thus embodies a convergence of molecular biology, chemistry, and bioengineering, catalyzing innovation at the interface of technology and medicine.
The collaborative effort, involving Tokyo University of Science and Tokyo University of Agriculture and Technology, was supported by AMED’s SICORP program, illustrating the power of international research partnerships. Published in the journal Biochemical and Biophysical Research Communications in January 2026, this seminal work charts a promising course toward revolutionizing Alzheimer’s diagnostics through advanced molecular tools.
This development resonates strongly within the broader scientific and medical communities, highlighting the growing role of aptamer technology beyond traditional antibody applications. As the demand for scalable, precise, and user-friendly diagnostic tools intensifies with aging demographics, innovations like these are set to redefine the landscape of neurodegenerative disease detection and management.
In sum, the discovery and validation of DNA aptamers MN711 and MN734 targeting NfL mark a paradigm shift in biomarker detection. By harnessing their high affinity, specificity, and adaptability, researchers are poised to usher in a new era of accessible, efficient, and cost-effective blood tests for Alzheimer’s disease and related neurodegenerative conditions. This leap forward not only promises improved patient outcomes through earlier diagnosis and monitoring but also accelerates the integration of next-generation biosensors in clinical practice.
Subject of Research: Not applicable
Article Title: Competitive-SELEX discovery of DNA aptamers selective for neurofilament light chain in human plasma
News Publication Date: 18-Jan-2026
References: DOI: 10.1016/j.bbrc.2025.153151
Image Credits: Dr. Kaori Tsukakoshi from Tokyo University of Science, Japan, and Dr. Kazunori Ikebukuro from Tokyo University of Agriculture and Technology, Japan
Keywords
Alzheimer disease, Dementia, Neuroscience, Biomarkers, DNA, Biotechnology, Biosensors, Medical diagnosis
Tags: advancements in Alzheimer’s diagnosticsaffordable blood tests for Alzheimer’santibody-free biomarker detectionDNA aptamer technology in neurologyDNA aptamers for Alzheimer’s detectionearly diagnosis of neurodegenerative diseasesinnovative blood biomarkers for brain diseasesneurodegeneration monitoring toolsneurofilament light chain blood biomarkersensitive blood assays for neurodegenerationsynthetic DNA aptamers specificityTokyo research on NfL detection
